Table 2. Characteristics of the 519 VTE patients who completed the survey, stratified by initial VTE treatment oral anticoagulant, and current anticoagulant: 2016.
| Initial anticoagulant treatment | Current anticoagulant treatment | ||||
|---|---|---|---|---|---|
| Warfarin | DOAC | Warfarin | DOAC | No OAC | |
| N | 338 | 181 | 218 | 196 | 105 |
| Age, mean | 47.3 | 42.7 | 47.8 | 44.5 | 43.6 |
| Age category, n (%) | |||||
| < 35 | 57 (16.9) | 51 (28.2) | 30 (13.8) | 44 (22.5) | 34 (32.4) |
| 35–44 | 99 (29.3) | 45 (24.9) | 64 (29.4) | 55 (28.1) | 25 (23.8) |
| 45–54 | 88 (26.0) | 56 (30.9) | 65 (29.8) | 57 (29.1) | 22 (21.0) |
| 55–64 | 50 (14.8) | 18 (9.9) | 31 (14.2) | 23 (11.7) | 14 (13.3) |
| 65+ | 44 (13.0) | 11 (6.1) | 28 (12.8) | 17 (8.7) | 10 (9.5) |
| Female, n (%) | 278 (82.3) | 151 (83.4) | 181 (83.0) | 157 (80.1) | 91 (86.7) |
| Race/ethnicity, n (%) | |||||
| White | 306 (90.5) | 164 (90.6) | 195 (89.5) | 178 (90.8) | 97 (92.4) |
| Black or African American | 12 (3.6) | 3 (1.7) | 8 (3.7) | 4 (2.0) | 3 (2.9) |
| Hispanic or Latino | 7 (2.1) | 6 (3.3) | 5 (2.3) | 5 (2.3) | 3 (2.9) |
| Asian American | 2 (0.6) | 1 (0.6) | 1 (0.5) | 2 (1.0) | 0 (0.0) |
| Other/not reported | 11 (3.3) | 7 (3.9) | 9 (4.1) | 7 (3.6) | 2 (1.9) |
| VTE initial treatment | |||||
| Warfarin | n/a | n/a | 205 (94.0) | 67 (34.2) | 66 (62.9) |
| DOAC | n/a | n/a | 13 (6.0) | 129 (65.8) | 39 (37.1) |
Abbreviations: DOAC, direct oral anticoagulant; OAC, oral anticoagulant; VTE, venous thromboembolism.